Q4 2024 Personalis Inc Earnings Call Transcript

Feb 27, 2025 / 10:00 PM GMT

Release Date Price: $4.24 (-5.36%)

Transcript 10-K8-K

Key Points

Positve

Personalis Inc (PSNL) reported a 15% increase in full-year revenue for 2024, reaching $84.6 million, driven by a 60% growth in biopharma revenue.
The company has a strong partnership with Moderna, extending their agreement for ongoing clinical trials, which is expected to be a key revenue driver in the next decade.
Personalis Inc (PSNL) successfully raised approximately $115 million in 2024, strengthening their cash position to $185 million, providing a strong liquidity position.
The company is on track to achieve CMS reimbursement for at least two indications in 2025, with submissions for breast cancer already made.
Personalis Inc (PSNL) has seen significant traction in the clinical marketplace, with a 52% increase in molecular tests delivered in the fourth quarter compared to the third quarter.

Negative

Total revenue for the fourth quarter of 2024 decreased by 15% compared to the same period in the prior year, primarily due to lower volume from certain customers.
Gross margin for 2025 is expected to be lower, in the range of 21% to 23%, due to the impact of investing in clinical test volume ahead of reimbursement.
The company anticipates a net loss of approximately $85 million in 2025, including $20 million of unreimbursed test costs.
Personalis Inc (PSNL) faces uncertainty in the timing of reimbursement decisions, which could impact revenue and gross margin projections.
The company is experiencing a decline in revenue from certain enterprise customers, which could affect overall revenue growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PSNL.OQ - Personalis Inc
Q4 2024 Personalis Inc Earnings Call
Feb 27, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, greetings and welcome to the Personalis 4th quarter, 2024 Onings conference call.

At this time, all participants are in a listen-only mode.

A brief question and answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please signal the operator by pressing and 0 on your telephone keypad.

As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Caroline Conner from Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.